Vectibix and Hair growth abnormal - a phase IV clinical study of FDA data

Summary:

Hair growth abnormal is found among people who take Vectibix, especially for people who are female, 50-59 old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Vectibix and have Hair growth abnormal. It is created by eHealthMe based on reports of 6,903 people who have side effects when taking Vectibix from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Jun, 30, 2022

6,903 people reported to have side effects when taking Vectibix.
Among them, 13 people (0.19%) have Hair growth abnormal.


What is Vectibix?

Vectibix has active ingredients of panitumumab. eHealthMe is studying from 6,912 Vectibix users for its effectiveness, alternative drugs and more.

What is Hair growth abnormal?

Hair growth abnormal is found to be associated with 1,064 drugs and 658 conditions by eHealthMe.

Number of Vectibix and Hair growth abnormal reports submitted per year:

Could Vectibix cause Hair growth abnormal?

Time on Vectibix when people have Hair growth abnormal *:

  • < 1 month: 33.33 %
  • 1 - 6 months: 33.33 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 33.33 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Hair growth abnormal when taking Vectibix *:

  • female: 66.67 %
  • male: 33.33 %

Age of people who have Hair growth abnormal when taking Vectibix *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 20 %
  • 40-49: 0.0 %
  • 50-59: 80 %
  • 60+: 0.0 %

Common drugs people take besides Vectibix *:

  1. Vitamins: 2 people, 15.38%
  2. Senna: 1 person, 7.69%
  3. Neulasta: 1 person, 7.69%

Common side effects people have besides Hair growth abnormal *:

  1. Rashes (redness): 8 people, 61.54%
  2. Paronychia (infection in the tissues adjacent to a nail on a finger or toe): 7 people, 53.85%
  3. Skin Fissures (a crack in the skin): 7 people, 53.85%
  4. Dry Skin: 6 people, 46.15%
  5. Stomatitis (inflammation of mucous membrane of mouth): 5 people, 38.46%
  6. Photosensitivity Reaction: 5 people, 38.46%
  7. Nausea (feeling of having an urge to vomit): 5 people, 38.46%
  8. Fatigue (feeling of tiredness): 4 people, 30.77%
  9. Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 4 people, 30.77%
  10. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 4 people, 30.77%

Common conditions people have *:

  1. Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 9 people, 69.23%
  2. Colon Cancer: 3 people, 23.08%
  3. Metastases To Lymph Nodes (cancer spreads to lymph node): 2 people, 15.38%
  4. Metastases To Liver (cancer spreads to liver): 2 people, 15.38%
  5. Metastases To Bone (cancer spreads to bone): 2 people, 15.38%
  6. Metastases To Adrenals (cancer spreads to adrenal gland of kidney): 2 people, 15.38%
  7. Malignant Peritoneal Neoplasm (cancer tumour of peritoneum): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Vectibix and have Hair growth abnormal?

Check whether Hair growth abnormal is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of Vectibix:

Hair growth abnormal treatments and more:

COVID vaccines that are related to Hair growth abnormal:

How severe was Hair growth abnormal and when was it recovered:

Expand to all the drugs that have ingredients of panitumumab:

Common drugs associated with Hair growth abnormal:

All the drugs that are associated with Hair growth abnormal:

Common conditions associated with Hair growth abnormal:

All the conditions that are associated with Hair growth abnormal:

How the study uses the data?

The study uses data from the FDA. It is based on panitumumab (the active ingredients of Vectibix) and Vectibix (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: